Literature DB >> 21922023

Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate Cancer.

Jeanny B Aragon-Ching1, William L Dahut.   

Abstract

Androgen deprivation therapy has been the mainstay of treatment for advanced and metastatic prostate cancer. The use of novel agents targeting the androgen receptor and its signaling pathways offers a promising approach that is both safe and effective. We describe the rationale behind the use of these compounds in clinical development and the existing challenges as to how best to incorporate these new and emerging therapies in the changing treatment paradigm of metastatic prostate cancer.

Entities:  

Year:  2010        PMID： 21922023      PMCID： PMC3172154          DOI： 10.1016/j.ddstr.2011.02.004

Source DB:  PubMed          Journal:  Drug Discov Today Ther Strateg        ISSN： 1740-6773


  38 in total

Review 1.  Molecular implications of the antiandrogen withdrawal syndrome.

Authors:  J W Moul; S Srivastava; D G McLeod
Journal:  Semin Urol       Date:  1995-05

Review 2.  Androgen receptor signaling in androgen-refractory prostate cancer.

Authors:  M E Grossmann; H Huang; D J Tindall
Journal:  J Natl Cancer Inst       Date:  2001-11-21       Impact factor: 13.506

3.  Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.

Authors:  Venkatesh D Handratta; Tadas S Vasaitis; Vincent C O Njar; Lalji K Gediya; Ritesh Kataria; Pankaj Chopra; Donnell Newman; Rena Farquhar; Zhiyong Guo; Yun Qiu; Angela M H Brodie
Journal:  J Med Chem       Date:  2005-04-21       Impact factor: 7.446

4.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.

Authors:  Alison H M Reid; Gerhardt Attard; Daniel C Danila; Nikhil Babu Oommen; David Olmos; Peter C Fong; L Rhoda Molife; Joanne Hunt; Christina Messiou; Christopher Parker; David Dearnaley; Joost F Swennenhuis; Leon W M M Terstappen; Gloria Lee; Thian Kheoh; Arturo Molina; Charles J Ryan; Eric Small; Howard I Scher; Johann S de Bono
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

5.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

6.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

7.  Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome.

Authors:  E J Small; P R Carroll
Journal:  Urology       Date:  1994-03       Impact factor: 2.649

8.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

Review 9.  CYP17 inhibition as a hormonal strategy for prostate cancer.

Authors:  Alison Hm Reid; Gerhardt Attard; Elaine Barrie; Johann S de Bono
Journal:  Nat Clin Pract Urol       Date:  2008-11

10.  Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer.

Authors:  A O'Donnell; I Judson; M Dowsett; F Raynaud; D Dearnaley; M Mason; S Harland; A Robbins; G Halbert; B Nutley; M Jarman
Journal:  Br J Cancer       Date:  2004-06-14       Impact factor: 7.640
View more
  4 in total

1.  Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less.

Authors:  Bo Li; Wenfu Lu; Zhenbang Chen
Journal:  Receptors Clin Investig       Date:  2014

2.  Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer.

Authors:  Anthony V Serritella; Daniel Shevrin; Elisabeth I Heath; James L Wade; Elia Martinez; Amanda Anderson; Joseph Schonhoft; Yen-Lin Chu; Theodore Karrison; Walter M Stadler; Russell Z Szmulewitz
Journal:  Clin Cancer Res       Date:  2022-04-14       Impact factor: 13.801

3.  Overexpression of α (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells.

Authors:  Naseruddin Höti; Shuang Yang; Yingwei Hu; Punit Shah; Michael C Haffner; Hui Zhang
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-01-16       Impact factor: 5.554

4.  Salinomycin Exerts Anticancer Effects on PC-3 Cells and PC-3-Derived Cancer Stem Cells In Vitro and In Vivo.

Authors:  Yunsheng Zhang; Luogen Liu; Fang Li; Tao Wu; Hongtao Jiang; Xianxun Jiang; Xiaobo Du; Yi Wang
Journal:  Biomed Res Int       Date:  2017-06-06       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.